Resistance to dopamine agonists in the treatment of prolactinomas: diagnostic criteria, mechanisms and ways to overcome it
The priority treatment approach for prolactinomas is therapy with dopamine agonists, which allows for elimination of clinical symptoms, normalization of prolactin levels, reduction of the adenoma size and prevention of metabolic abnormalities in the majority of patients. Nevertheless, 10 to 20% of p...
Main Authors: | Irena A. Ilovayskaya, Gulnar R. Vagapova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
MONIKI
2023-12-01
|
Series: | Alʹmanah Kliničeskoj Mediciny |
Subjects: | |
Online Access: | https://almclinmed.ru/jour/article/viewFile/17192/1622 |
Similar Items
-
The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas
by: Xiaoshuang Liu, et al.
Published: (2019-01-01) -
The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis
by: Yunzhi Zou, et al.
Published: (2021-11-01) -
Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms
by: Claudia Pivonello, et al.
Published: (2022-01-01) -
The course of pregnancy and delivery in patients with prolactinoma during treatment with cabergoline
by: Larisa Dzeranova, et al.
Published: (2016-11-01) -
Prolactinomas: evolution after menopause
by: Maria Susana Mallea-Gil, et al.